The plausible explanations for the improved outcomes of the combination might involve several mechanisms, such as increased sensitivity of cancer cells to immunotherapy via increase of mutation burden, upregulation of PD-L1 expression, and restoration of exhausted immune cells by chemotherapeutic agents (44, 45). Here, CD274 is linked to cancer.